Ofloxacin Articles
Diapharm organizes GMP inspection at Ranbaxy
13 May 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
Consilient moves into UK and Dutch generics market
22 August 2005
Akorn debuts two ophthalmic drug products
9 May 2005
Daiichi Pharma
23 August 2004
Cravit boosts Daiichi, beats expectations
10 November 2003
Par Pharma starts shipping ofloxacin
8 September 2003
Teva gains US approval for generic ofloxacin
8 September 2003
Japan pharma stock market - week to October 15
17 October 2001
Cipla signs deal with IVAX affiliate
5 September 2001
Ranbaxy 1st-quarter profits rise 47%
4 May 2001
India's Ranbaxy eyes French generics mart
12 January 2001
Daiichi takes over Thai joint venture
15 September 2000
Stock Commentary Tokyo
19 April 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
Hoechst Sales Down 18% But HMR Pipeline Strong
19 August 1998
Magainin Files For Pexiganan In USA
28 July 1998
Daiichi Sets Up Japanese JV
3 June 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
China: Foreign Drug Investment Categories
10 March 1998
Daiichi Launches Floxin For Otitis
26 February 1998
Second Trial Positive For Magainin's Cytolex
2 October 1997
Strong $ Impact On 1st Qtr At Johnson & Johnson
22 April 1997
Magainin Moves Nearer To Marketing Peptide Antibiotic
22 April 1997
Magainin And SB In Cytolex Deal
24 February 1997
Daiichi Submits NDA For Ofloxacin
13 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Ofloxacin Approval For Allergan
10 June 1996
Marainin Pharma: MSI-78 Phase III trials
18 September 1995
FDA Panel Turns Down Monurol NDA
31 July 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
MMD Essential To Hoechst For Leading Pharma Role
3 April 1995
End Of Year Encouraging For US Companies
6 February 1995
Daiichi Sales "Exceeding Targets"
30 January 1995
Mixed Six Month Results From Japan's Drugmakers
9 January 1995
TOKYO STOCK COMMENT
2 January 1995
Tokyo Stock Comment
5 December 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Stability, Consensus And Competition Needed In Germany
3 October 1994
EISAI'S SALES AHEAD IN FLAT JAPANESE SECTOR
6 June 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
LIGHT AT THE END OF THE TUNNEL FOR HOECHST?
28 March 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
JAPANESE FIRST-HALF RESULTS AND FORECASTS
6 December 1993
HOECHST PHARMA SALES ON THE SLIDE
25 October 1993
NEW PRODUCTS APPROVED BY JAPAN'S CPAC
27 September 1993
DAIICHI IN CHINA
23 August 1993
OCUFLOX APPROVED IN USA
16 August 1993
DAIICHI ENTERING NEW PRODUCT PHASE
26 July 1993
GERMAN PATENT COVER "THREAT"
19 April 1993
NEW LOMEFLOXACIN EFFICACY DATA
19 April 1993
HOECHST DISSATISFIED WITH 1992 RESULTS
29 March 1993
QUINOLONE SAFETY NOTED BY CSM
15 March 1993
DAIICHI'S DU-6859
8 March 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
DAIICHI'S DEMENTIA DRUG: FILING IN 1993?
4 January 1993
US RESULTS 3RD QTR
2 November 1992
Daiichi expects improvement in 92
22 June 1992
Hoechst launches Tarivid infusion in UK
22 June 1992
HOECHST'S TARIVID FOR NF PATIENTS
11 May 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
Showing 1-71 of 71 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
